Intrinsic Value of S&P & Nasdaq Contact Us

Nanobiotix S.A. NNBXF OTC

Other OTC • Healthcare • Biotechnology • FR • USD

SharesGrow Score
30/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Nanobiotix S.A. (NNBXF) is a Biotechnology company in the Healthcare sector, currently trading at $9.10. It has a SharesGrow Score of 27/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is -$12M, +16016.9%/yr average growth. Net income is $68M (loss), growing at -20.9%/yr. Net profit margin is 0% (thin). Gross margin is 100% (-26370 pp trend).

Balance sheet: total debt is $51M with negative equity of -$66M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.04 (adequate). Debt-to-assets is 75.5%. Total assets: $67M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 25/100 (Fail), Moat 35/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

NNBXF SharesGrow Score Overview

39/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 25/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 35/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Stock Chart & Stats

Market Data
52-Week Range7.32-19.85
Volume100
Avg Volume (30D)64
Beta (1Y)0.00
Share Statistics
EPS (TTM)-1.44
Shares Outstanding$47.27M
IPO Date2020-01-21
Employees103
CEOLaurent Levy
Financial Highlights & Ratios
Revenue (TTM)$-11.61M
Gross Profit$-11.61M
EBITDA$-58.32M
Net Income$-68.13M
Operating Income$-68.39M
Total Cash$49.74M
Total Debt$50.9M
Net Debt$1.17M
Total Assets$67.42M
Price / Earnings (P/E)-6.3
Analyst Forecast
Company Info
CountryFR
ExchangeOther OTC
CurrencyUSD

Price Chart

NNBXF
Nanobiotix S.A.  ·  Other OTC
Healthcare • Biotechnology
7.32 52WK RANGE 19.85
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message